secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001628280-25-012022
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology reports record Q3 revenue $17.0M, net income $4.5M, first data licensing deal up to $8M
--------------------------------------------------------------------------------

- Revenue up 42% YoY to $17.0M; net income of $4.5M vs loss of $2.6M in prior year quarter.
- Adjusted EBITDA $5.2M; gross margin improved to 61% from prior 35% on cost reductions.
- Signed first major data licensing agreement worth up to $8.0M; hired Matt Newman as EVP/GM for data platform.
- Year-to-date revenue $44.6M (+23% YoY); net income $6.5M vs loss of $7.1M in prior nine months.
- No debt; cash $3.2M; expects quarterly revenue fluctuations but positioned for sustained profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828025012022/0001628280-25-012022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828025012022/csbr-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-012022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer